| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10594101 | Bioorganic & Medicinal Chemistry Letters | 2011 | 4 Pages |
Abstract
As an approach to treatment of advanced prostate cancer, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to androgen receptor downregulator (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Robert H. Bradbury, Neil J. Hales, Alfred A. Rabow, Graeme E. Walker, David G. Acton, David M. Andrews, Peter Ballard, Nigel A.N. Brooks, Nicola Colclough, Alan Girdwood, Urs J. Hancox, Owen Jones, David Jude, Sarah A. Loddick, Andrew A. Mortlock,